Amarin Corporation Plc ( (AMRN) ) has released its Q2 earnings. Here is a breakdown of the information Amarin Corporation Plc presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amarin Corporation Plc is a pharmaceutical company focused on cardiovascular disease management, known for its product VASCEPA, which is used to reduce cardiovascular risk in patients. In its second quarter of 2025, Amarin reported an 8% increase in total net revenue, driven by its strategic partnership with Recordati for the commercialization of VAZKEPA in Europe. Despite a decrease in U.S. sales, the company saw significant growth in European and Rest-of-World markets. The company also initiated a global restructuring plan aimed at saving $70 million in operating expenses over the next year. Key financial highlights include a net loss of $14.1 million and a strong cash position of nearly $300 million. Looking forward, Amarin’s management is optimistic about achieving positive free cash flow and expanding the market reach of VASCEPA/VAZKEPA globally.